Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | ERCC5 | P28715 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | QPCT | Q16769 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13833764 | 0.70 | GAA (0.36) | BRD4KCNA3ERCC5FEN1PDPK1 | |
| SCHEMBL13377309 | 0.67 | POLB (0.35) | BRD4SMN1; SMN2QPCT | |
| SCHEMBL23201571 | 0.66 | BRD4 (0.41) | BRD4BRD9BRD7 | |
| SCHEMBL13377326 | 0.66 | CNOT7 (0.33) | BRD4 | |
| SCHEMBL22729431 | 0.66 | GPR35 (0.39) | BRD4ERCC5FEN1 | |
| SCHEMBL13377395 | 0.63 | KCNA3 (0.42) | BRD4KCNA3SMN1; SMN2 | |
| SCHEMBL13377364 | 0.63 | BRD4 (0.35) | BRD4ERCC5FEN1BRD9BRD7 | |
| SCHEMBL14194611 | 0.63 | BRD4 (0.45) | BRD4BRD9BRD7 | |
| SCHEMBL13377335 | 0.63 | BRD4 (0.33) | BRD4BRD9BRD7 | |
| SCHEMBL13377347 | 0.62 | BRD4 (0.32) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099561-A1 | HETEROBICYCLIC ALKYLTHIO-BRIDGED ISOXAZOLINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099561-A1 | HETEROBICYCLIC ALKYLTHIO-BRIDGED ISOXAZOLINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099561-A1 | HETEROBICYCLIC ALKYLTHIO-BRIDGED ISOXAZOLINES | UQCRB, CCNB3, CCNB1 | BRD4 370/4885KCNA3 501/4885ERCC5 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.